No products in the cart.
Mouse Monoclonal p300 antibody [7D8A6] (STJ98299)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-1:2000; ELISA 1:10000
Recommended protocols: check protocols
Click or hover above images to see image description for p300 Monoclonal Antibody.
Check alternative names for the antibodyExpand
EP300 antibody, P300 antibody,|E1A associated protein p300 antibody|E1A binding protein p300 antibody|E1A-associated protein p300 antibody|EP300 antibody|EP300: E1A binding protein p300 antibody|EP300_HUMAN antibody|Histone acetyltransferase p300 antibody|KAT3B antibody|p300 HAT antibody|RSTS2 antibody|Anti-KAT3B / p300 antibody [3G230 / NM-11] – ChIP Grade (ab14984)
SCBT cat No: sc-585|sc-48343|sc-8981|sc-584|sc-32244|sc-56455|sc-160635|
p300 Monoclonal Antibody
|Catalogue No.|| |
p300 Monoclonal Antibody detects endogenous levels of p300 protein.
Purified recombinant fragment of p300 expressed in E Coli
|Recommended dilution|| |
WB 1:500-1:2000; ELISA 1:10000
p300 Antibody was tube-contained. Ascitic fluid containing 0.03% sodium azide.
p300 Antibody was purified using affinity purification.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Histone acetyltransferase p300 antibody, p300 HAT antibody, E1A-associated protein p300 antibody
|Protein names|| |
Histone acetyltransferase p300 , p300 HAT , E1A-associated protein p300
|Protein function|| |
Functions as histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Mediates acetylation of histone H3 at ‘Lys-122’ (H3K122ac), a modification that localizes at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Mediates acetylation of histone H3 at ‘Lys-27’ (H3K27ac). Also functions as acetyltransferase for nonhistone targets. Acetylates ‘Lys-131’ of ALX1 and acts as its coactivator. Acetylates SIRT2 and is proposed to indirectly increase the transcriptional activity of TP53 through acetylation and subsequent attenuation of SIRT2 deacetylase function. Acetylates HDAC1 leading to its inactivation and modulation of transcription. Acts as a TFAP2A-mediated transcriptional coactivator in presence of CITED2. Plays a role as a coactivator of NEUROD1-dependent transcription of the secretin and p21 genes and controls terminal differentiation of cells in the intestinal epithelium. Promotes cardiac myocyte enlargement. Can also mediate transcriptional repression. Binds to and may be involved in the transforming capacity of the adenovirus E1A protein. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat’s transactivating activity and may help inducing chromatin remodeling of proviral genes. Acetylates FOXO1 and enhances its transcriptional activity. Acetylates BCL6 wich disrupts its ability to recruit histone deacetylases and hinders its transcriptional repressor activity. Participates in CLOCK or NPAS2-regulated rhythmic gene transcription; exhibits a circadian association with CLOCK or NPAS2, correlating with increase in PER1/2 mRNA and histone H3 acetylation on the PER1/2 promoter. Acetylates MTA1 at ‘Lys-626’ which is essential for its transcriptional coactivator activity . Acetylates XBP1 isoform 2; acetylation increases protein stability of XBP1 isoform 2 and enhances its transcriptional activity . Acetylates PCNA; acetylation promotes removal of chromatin-bound PCNA and its degradation during nucleotide excision repair (NER) . Acetylates MEF2D. / Acetyl-CoA + [histone] = CoA + acetyl-[histone].
|Involvement in disease|| |
Note: Defects in EP300 may play a role in epithelial cancer.; Note: Chromosomal aberrations involving EP300 may be a cause of acute myeloid leukemias. Translocation t(8;22)(p11;q13) with KAT6A.; Rubinstein-Taybi syndrome 2 (RSTS2) [MIM:613684]: A disorder characterized by craniofacial abnormalities, postnatal growth deficiency, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies. Some individuals with RSTS2 have less severe mental impairment, more severe microcephaly, and a greater degree of changes in facial bone structure than RSTS1 patients. . Note: The disease is caused by mutations affecting the gene represented in this entry.
|Protein sequence and domain|| |
The CRD1 domain (cell cycle regulatory domain 1) mediates transcriptional repression of a subset of p300 responsive genes; it can be de-repressed by CDKN1A/p21WAF1 at least at some promoters. It conatins sumoylation and acetylation sites and the same lysine residues may be targeted for the respective modifications. It is proposed that deacetylation by SIRT1 allows sumoylation leading to suppressed activity. / Contains 1 bromo domain. / Contains 1 CBP/p300-type HAT (histone acetyltransferase) domain. / Contains 1 KIX domain. / Contains 2 TAZ-type zinc fingers. / Contains 1 ZZ-type zinc finger.
|Protein post-translational modifications|| |
Acetylated on Lys at up to 17 positions by intermolecular autocatalysis. Deacetylated in the transcriptional repression domain (CRD1) by SIRT1, preferentially at Lys-1020. Deacetylated by SIRT2, preferentially at Lys-418, Lys-423, Lys-1542, Lys-1546, Lys-1549, Lys-1699, Lys-1704 and Lys-1707. / Citrullinated at Arg-2142 by PADI4, which impairs methylation by CARM1 and promotes interaction with NCOA2/GRIP1. / Methylated at Arg-580 and Arg-604 in the KIX domain by CARM1, which blocks association with CREB, inhibits CREB signaling and activates apoptotic response. Also methylated at Arg-2142 by CARM1, which impairs interaction with NCOA2/GRIP1. / Sumoylated; sumoylation in the transcriptional repression domain (CRD1) mediates transcriptional repression. Desumoylated by SENP3 through the removal of SUMO2 and SUMO3. / Probable target of ubiquitination by FBXO3, leading to rapid proteasome-dependent degradation. / Phosphorylated by HIPK2 in a RUNX1-dependent manner. This phosphorylation that activates EP300 happens when RUNX1 is associated with DNA and CBFB. Phosphorylated by ROCK2 and this enhances its activity. Phosphorylation at Ser-89 by AMPK reduces interaction with nuclear receptors, such as PPARG.
|Protein cellular localization|| |
Cytoplasm / Nucleus
AntibodyPlus can customize p300 Antibody according to your requirement, including bulk product size,etc. Please contact email@example.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: